ImmunityBio Releases New Survey Data Highlighting NMIBC Patient Treatment Preferences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 22 2026
0mins
ImmunityBio announced new survey data highlighting the diverse treatment preferences and decision-making priorities of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-invasive bladder cancer. The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research 2026, May 17-20, 2026, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. The mixed-methods study, conducted in partnership with Fight Bladder Cancer, a UK-based patient advocacy organization, explored how patients with NMIBC who were currently receiving or had previously received BCG weigh radical cystectomy against bladder-sparing therapies following BCG treatment failure. The study provides a contemporary, patient-centered perspective on the factors influencing treatment decision-making in this setting. The study used an online questionnaire completed by 86 UK adults living with NMIBC who were currently receiving or had previously been treated with BCG. This survey data was supplemented by one-on-one interviews and focus group discussions. Together, these methods were designed to evaluate treatment experiences, priorities, and trade-off preferences related to bladder-sparing approaches versus radical cystectomy following BCG failure. The data showed that treatment preferences among UK patients with NMIBC are highly individualized, shaped by past treatment experiences, personal values, and age. Key findings include: Patients actively receiving BCG were more likely to favor bladder preservation strategies Patients who had previously undergone radical cystectomy were more likely to support repeating that decision; Older participants demonstrated a lower preference for radical cystectomy; Clinical effectiveness, including impact on recurrence, progression, and life expectancy, was identified as the most important factor influencing treatment decisions; Lifestyle disruption and quality-of-life considerations varied across patients, with male participants expressing greater concern regarding the daily-life impact of radical cystectomy. The authors concluded that UK adults living with NMIBC have widely varying treatment priorities-some placing greater weight on cancer control and life expectancy, while others prioritize quality of life and bladder preservation-with many willing to accept trade-offs, such as more frequent hospital visits, to avoid radical cystectomy. Taken together, the findings underscore that there is no one-size-fits-all approach to treatment decisions in this population, and highlight the importance of individualized, patient-centered care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.440
Low
5.00
Averages
7.33
High
9.00
Current: 9.440
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Director Cheryl Cohen Sells 131,210 Shares
- Executive Sell-off: On July 2, 2026, ImmunityBio's Director Cheryl Cohen sold 131,210 shares for a total of $1,246,941, indicating a cautious outlook on the company's future prospects.
- Market Reaction: This sell-off may raise investor concerns regarding ImmunityBio's stock price, particularly as executives choosing to sell large amounts of shares at this time could be interpreted as a lack of confidence in the company's performance.
- Liquidity Impact: The transaction allows Cohen to secure over $1.24 million in liquid funds, which may be used for personal investments or other financial needs, potentially influencing market perceptions of her financial situation.
- Governance Implications: The executive sell-off could prompt scrutiny of ImmunityBio's corporate governance structure, as investors may question the confidence of insiders in the company's future direction, thereby affecting shareholder trust.
See More
Sellas Life Sciences Stock Gains Retail Trader Favor Amid Bullish Sentiment
- Retail Trader Enthusiasm: In a poll of 3,400 users, Sellas Life Sciences (SLS) garnered 50% of the votes, significantly outpacing Ondas Holdings at 24% and ImmunityBio at 18%, indicating strong investor confidence in its future potential.
- Clinical Trial Progress: Sellas' Phase 3 Regal trial in acute myeloid leukemia (AML) has reached 78 of the 80 events needed for final analysis, making the next two events critical catalysts that could drive stock price volatility.
- Acquisition Speculation: CEO Angelos Stergiou's optimistic remarks on social media and gratitude towards strategic partners have intensified market speculation regarding potential buyouts, likely attracting more investor interest.
- Significant Market Value Increase: Sellas' market value surged from $73 million at the start of 2024 to over $1.5 billion by mid-2026, reflecting heightened investor attention around the Regal readout, while the company ended Q1 with $107.1 million in cash, showcasing a robust financial position.
See More
ImmunityBio Officer Plans to Sell 131,210 Shares
- Insider Selling Plan: ImmunityBio officer Cheryl L. Cohen filed a regulatory notice to sell 131,210 shares of IBRX stock, valued at approximately $1.21 million, which may impact market sentiment, causing retail investor confidence to drop from 'extremely bullish' to 'bullish'.
- Source of Shares: Cohen's shares stem from a stock-option exercise on July 2 and restricted stock units acquired in 2021, comprising 55,979 option shares and 75,231 restricted shares, indicating potential challenges to executive confidence in the company's future.
- Anktiva Expansion Outlook: Investors are closely monitoring ImmunityBio's FDA application progress in the bladder cancer sector, as the FDA has accepted its application to expand Anktiva, with a target decision date of January 6, 2027, which could further drive company performance if approved.
- Financial Performance and Market Reaction: Despite a 168% year-over-year increase in net sales to $44.2 million in Q1, ImmunityBio's net loss widened to $632.8 million, intensifying investor anticipation for future sales data, which may influence stock price volatility.
See More
ImmunityBio Shares Rise as Market Eyes July Catalysts
- Significant Sales Growth: ImmunityBio's Anktiva drove a 168% increase in Q1 net sales to $44.2 million, exceeding Wall Street estimates, indicating strong market demand that is expected to further enhance the company's overall performance.
- FDA Expansion Filing Accepted: The FDA has accepted ImmunityBio's filing for Anktiva's expansion to patients with papillary bladder cancer, with a target decision date of January 6, 2027, which could open new market opportunities and strengthen its competitive position in cancer treatment.
- Market Sentiment Turns Bullish: With a 248% surge in message volume on social media, retail traders' sentiment towards ImmunityBio has flipped from bearish to bullish, indicating strong market anticipation for upcoming July catalysts that may drive further stock price increases.
- Automation Manufacturing Platform Gains Attention: ImmunityBio is developing the world's first NK cell automation manufacturing robot, expected to enhance production efficiency and reduce costs, and investor confidence in the company's growth potential has surged following Soon-Shiong's latest updates.
See More
SLS and IBRX Seize Opportunities in Biotech Sector
- Biotech Market Performance: The SPDR S&P Biotech ETF (XBI) rose 17% in June, with Sellas Life Sciences (SLS) surging 53% and ImmunityBio (IBRX) gaining 10%, indicating a strong recovery in the biotech sector that has captured investor interest.
- Innovative Treatment Progress: Sellas is conducting a pivotal Phase 3 trial for GPS targeting acute myeloid leukemia (AML), having reached 78 out of 80 events needed for final analysis, suggesting patients may be living longer than expected, which boosts market confidence in its future.
- M&A Activity Expectations: Edison Investment Research notes that M&A activity in the biotech sector may persist due to clearer policies, attractive valuations, and high innovation levels, especially following Sellas's updates on executive severance and change-of-control arrangements, intensifying market speculation about a potential acquisition.
- FDA Support for Innovation: Edison emphasizes the FDA's support for medical innovation, with expectations for continued accelerated review pathways and flexibility, as evidenced by 52 new molecular entities approved in 2025, close to the 10-year average, reflecting a positive regulatory environment.
See More
IBRX Poised for Potential Inclusion in Russell 1000 Index
- Market Capitalization Advantage: IBRX's current market capitalization of approximately $9 billion significantly exceeds the $5.7 billion threshold for the Russell 1000 Index, positioning it as a strong candidate for inclusion that could attract passive investment inflows.
- ANKTIVA Sales Growth: The accelerating sales of IBRX's ANKTIVA product in the U.S. have been bolstered by the FDA's April 2024 approval for use in BCG-unresponsive non-muscle invasive bladder cancer, which is expected to further drive the company's revenue growth.
- Investor Sentiment Optimism: Retail investor sentiment around IBRX has remained in the 'bullish' territory over the past 24 hours, with message volume increasing by approximately 154% year-over-year, indicating strong market interest in its future performance.
- Stock Price Surge: IBRX shares jumped 12% on Friday, and if gains hold, it would mark the stock's best day since late March, reflecting investor expectations for its potential inclusion in the Russell 1000 and optimism about future earnings.
See More
ImmunityBio Director Cheryl Cohen Sells 131,210 Shares
- Executive Sell-off: On July 2, 2026, ImmunityBio's Director Cheryl Cohen sold 131,210 shares for a total of $1,246,941, indicating a cautious outlook on the company's future prospects.
- Market Reaction: This sell-off may raise investor concerns regarding ImmunityBio's stock price, particularly as executives choosing to sell large amounts of shares at this time could be interpreted as a lack of confidence in the company's performance.
- Liquidity Impact: The transaction allows Cohen to secure over $1.24 million in liquid funds, which may be used for personal investments or other financial needs, potentially influencing market perceptions of her financial situation.
- Governance Implications: The executive sell-off could prompt scrutiny of ImmunityBio's corporate governance structure, as investors may question the confidence of insiders in the company's future direction, thereby affecting shareholder trust.
See More
Sellas Life Sciences Stock Gains Retail Trader Favor Amid Bullish Sentiment
- Retail Trader Enthusiasm: In a poll of 3,400 users, Sellas Life Sciences (SLS) garnered 50% of the votes, significantly outpacing Ondas Holdings at 24% and ImmunityBio at 18%, indicating strong investor confidence in its future potential.
- Clinical Trial Progress: Sellas' Phase 3 Regal trial in acute myeloid leukemia (AML) has reached 78 of the 80 events needed for final analysis, making the next two events critical catalysts that could drive stock price volatility.
- Acquisition Speculation: CEO Angelos Stergiou's optimistic remarks on social media and gratitude towards strategic partners have intensified market speculation regarding potential buyouts, likely attracting more investor interest.
- Significant Market Value Increase: Sellas' market value surged from $73 million at the start of 2024 to over $1.5 billion by mid-2026, reflecting heightened investor attention around the Regal readout, while the company ended Q1 with $107.1 million in cash, showcasing a robust financial position.
See More
ImmunityBio Officer Plans to Sell 131,210 Shares
- Insider Selling Plan: ImmunityBio officer Cheryl L. Cohen filed a regulatory notice to sell 131,210 shares of IBRX stock, valued at approximately $1.21 million, which may impact market sentiment, causing retail investor confidence to drop from 'extremely bullish' to 'bullish'.
- Source of Shares: Cohen's shares stem from a stock-option exercise on July 2 and restricted stock units acquired in 2021, comprising 55,979 option shares and 75,231 restricted shares, indicating potential challenges to executive confidence in the company's future.
- Anktiva Expansion Outlook: Investors are closely monitoring ImmunityBio's FDA application progress in the bladder cancer sector, as the FDA has accepted its application to expand Anktiva, with a target decision date of January 6, 2027, which could further drive company performance if approved.
- Financial Performance and Market Reaction: Despite a 168% year-over-year increase in net sales to $44.2 million in Q1, ImmunityBio's net loss widened to $632.8 million, intensifying investor anticipation for future sales data, which may influence stock price volatility.
See More
ImmunityBio Shares Rise as Market Eyes July Catalysts
- Significant Sales Growth: ImmunityBio's Anktiva drove a 168% increase in Q1 net sales to $44.2 million, exceeding Wall Street estimates, indicating strong market demand that is expected to further enhance the company's overall performance.
- FDA Expansion Filing Accepted: The FDA has accepted ImmunityBio's filing for Anktiva's expansion to patients with papillary bladder cancer, with a target decision date of January 6, 2027, which could open new market opportunities and strengthen its competitive position in cancer treatment.
- Market Sentiment Turns Bullish: With a 248% surge in message volume on social media, retail traders' sentiment towards ImmunityBio has flipped from bearish to bullish, indicating strong market anticipation for upcoming July catalysts that may drive further stock price increases.
- Automation Manufacturing Platform Gains Attention: ImmunityBio is developing the world's first NK cell automation manufacturing robot, expected to enhance production efficiency and reduce costs, and investor confidence in the company's growth potential has surged following Soon-Shiong's latest updates.
See More
SLS and IBRX Seize Opportunities in Biotech Sector
- Biotech Market Performance: The SPDR S&P Biotech ETF (XBI) rose 17% in June, with Sellas Life Sciences (SLS) surging 53% and ImmunityBio (IBRX) gaining 10%, indicating a strong recovery in the biotech sector that has captured investor interest.
- Innovative Treatment Progress: Sellas is conducting a pivotal Phase 3 trial for GPS targeting acute myeloid leukemia (AML), having reached 78 out of 80 events needed for final analysis, suggesting patients may be living longer than expected, which boosts market confidence in its future.
- M&A Activity Expectations: Edison Investment Research notes that M&A activity in the biotech sector may persist due to clearer policies, attractive valuations, and high innovation levels, especially following Sellas's updates on executive severance and change-of-control arrangements, intensifying market speculation about a potential acquisition.
- FDA Support for Innovation: Edison emphasizes the FDA's support for medical innovation, with expectations for continued accelerated review pathways and flexibility, as evidenced by 52 new molecular entities approved in 2025, close to the 10-year average, reflecting a positive regulatory environment.
See More
IBRX Poised for Potential Inclusion in Russell 1000 Index
- Market Capitalization Advantage: IBRX's current market capitalization of approximately $9 billion significantly exceeds the $5.7 billion threshold for the Russell 1000 Index, positioning it as a strong candidate for inclusion that could attract passive investment inflows.
- ANKTIVA Sales Growth: The accelerating sales of IBRX's ANKTIVA product in the U.S. have been bolstered by the FDA's April 2024 approval for use in BCG-unresponsive non-muscle invasive bladder cancer, which is expected to further drive the company's revenue growth.
- Investor Sentiment Optimism: Retail investor sentiment around IBRX has remained in the 'bullish' territory over the past 24 hours, with message volume increasing by approximately 154% year-over-year, indicating strong market interest in its future performance.
- Stock Price Surge: IBRX shares jumped 12% on Friday, and if gains hold, it would mark the stock's best day since late March, reflecting investor expectations for its potential inclusion in the Russell 1000 and optimism about future earnings.
See More
